Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. grew its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 125.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,997 shares of the company's stock after acquiring an additional 67,276 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.12% of Intellia Therapeutics worth $1,411,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Elmwood Wealth Management Inc. lifted its position in shares of Intellia Therapeutics by 0.9% in the third quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company's stock worth $1,393,000 after purchasing an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock worth $77,000 after buying an additional 794 shares in the last quarter. Capstone Investment Advisors LLC increased its stake in Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company's stock valued at $1,256,000 after acquiring an additional 831 shares during the period. KBC Group NV raised its holdings in Intellia Therapeutics by 37.3% in the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Axxcess Wealth Management LLC lifted its position in shares of Intellia Therapeutics by 5.4% in the 3rd quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company's stock worth $415,000 after acquiring an additional 1,044 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NTLA has been the topic of a number of recent analyst reports. The Goldman Sachs Group reduced their price objective on Intellia Therapeutics from $19.00 to $12.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 14th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. William Blair reiterated a "neutral" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research note on Monday, November 18th. Oppenheimer decreased their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Finally, Wedbush restated a "neutral" rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $51.06.

Insider Activity at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 28,735 shares of company stock worth $349,909. Corporate insiders own 3.20% of the company's stock.

Intellia Therapeutics Trading Up 0.8 %

Shares of NTLA traded up $0.08 on Friday, reaching $9.50. The stock had a trading volume of 3,327,352 shares, compared to its average volume of 2,148,948. The company has a 50-day simple moving average of $13.15 and a 200-day simple moving average of $18.51. Intellia Therapeutics, Inc. has a 12-month low of $9.25 and a 12-month high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analysts' expectations of $8.28 million. The business's revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.38) earnings per share. Equities research analysts predict that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.